Pharmaceuticals, Biotechnology and Life Sciences
Portola Pharmaceuticals said that it will present an abstract about results from its trial in Phase 3b/4 of its investigational…
Portola Pharmaceuticals has resubmitted its Biologics License Application (BLA) to the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) for AndexXa (andexanet alfa), a reversal agent for Factor Xa inhibitors.
Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.